Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 19 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) is a rare, inherited eye disease caused by mutations in the CAPN5 gene, which encodes the enzyme calpain-5 in retinal photoreceptor cells. Over decades, it leads to chronic inflammation, abnormal blood vessel growth, fibrotic scarring, and progressive vision loss,...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) is a rare, inherited eye disease caused by mutations in the CAPN5 gene, which encodes the enzyme calpain-5 in retinal photoreceptor cells. Over decades, it leads to chronic inflammation, abnormal blood vessel growth, fibrotic scarring, and progressive vision loss, ultimately resulting in complete blindness if untreated PLOSPLOS. Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) is a rare, inherited eye disease...

Key Takeaways

  • This article explains Types (Stages) in simple medical language.
  • This article explains Causes in simple medical language.
  • This article explains Symptoms in simple medical language.
  • This article explains Diagnostic Tests in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Sudden vision loss, severe eye pain, new flashes, or many new floaters.
  • Eye symptoms after injury or chemical exposure.
  • Rapidly worsening redness, swelling, or vision changes.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) is a rare, inherited eye disease caused by mutations in the CAPN5 gene, which encodes the enzyme calpain-5 in retinal photoreceptor cells. Over decades, it leads to chronic infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation, abnormal blood vessel growth, fibrotic scarring, and progressive vision loss, ultimately resulting in complete blindness if untreated PLOSPLOS.

Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) is a rare, inherited eye disease caused by mutations in the CAPN5 gene, which encodes the calcium-activated protease calpain-5. Over decades, patients develop progressive infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation of the uveal tract (uveitis), degeneration of photoreceptors (like retinitis pigmentosa), and abnormal new blood vessel growth (neovascularization) in the retina and iris, often complicated by vitreous hemorrhage and tractional retinal detachment EyeWikiPLOS.
Most affected families harbor missense mutations (e.g., Arg243Leu, Leu244Pro) in the catalytic domain of CAPN5, leading to mislocalization of the enzyme and dysregulated proteolysis that triggers infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation and angiogenesis EyeWikiPMC. Clinically, ADNIV typically begins in the second or third decade of life and follows five stages—initial uveitis, photoreceptor loss, retinal neovascularization, intraocular chronic injury or inflammation. সহজ বাংলা: অতিরিক্ত দাগের মতো টিস্যু তৈরি হওয়া।" data-rx-term="fibrosis" data-rx-definition="Fibrosis means excess scar-like tissue formation after chronic injury or inflammation. সহজ বাংলা: অতিরিক্ত দাগের মতো টিস্যু তৈরি হওয়া।">fibrosis with detachment, and finally phthisis bulbi (eye shrinkage) PLOSPMC.

ADNIV is unique in that it mimics common eye conditions at different stages: it begins like an autoimmune uveitis, evolves into a degeneration resembling retinitis pigmentosa, then progresses to a proliferative diabetic retinopathy–type neovascularization, and finally to fibrotic tractional retinal detachment, neovascular glaucoma, and phthisis bulbi PLOSPLOS.

Types (Stages)

ADNIV advances through five chronologic stages, each roughly a decade long. Below are descriptions of each stage:

Stage I

In stage I, patients exhibit mild, non-infectious uveitis with occasional white blood cells in the vitreous and a subtle reduction in the ERG b-wave, although the retina appears normal on exam PLOS.

Stage II

Stage II resembles retinitis pigmentosa as photoreceptor cells begin degenerating, leading to peripheral pigmentary changes and early cataract formation PLOS.

Stage III

In stage III, abnormal new blood vessels form on the retina and iris—similar to proliferative diabetic retinopathy—often resulting in cystoid macular edema and floaters from early hemorrhage PLOS.

Stage IV

Stage IV is marked by intraocular chronic injury or inflammation. সহজ বাংলা: অতিরিক্ত দাগের মতো টিস্যু তৈরি হওয়া।" data-rx-term="fibrosis" data-rx-definition="Fibrosis means excess scar-like tissue formation after chronic injury or inflammation. সহজ বাংলা: অতিরিক্ত দাগের মতো টিস্যু তৈরি হওয়া।">fibrosis. Fibrotic membranes contract, causing tractional retinal detachments and more extensive vitreous hemorrhages, which significantly impair vision PLOS.

Stage V

The final stage involves relentless infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation, widespread hemorrhage, neovascular glaucoma, ongoing chronic injury or inflammation. সহজ বাংলা: অতিরিক্ত দাগের মতো টিস্যু তৈরি হওয়া।" data-rx-term="fibrosis" data-rx-definition="Fibrosis means excess scar-like tissue formation after chronic injury or inflammation. সহজ বাংলা: অতিরিক্ত দাগের মতো টিস্যু তৈরি হওয়া।">fibrosis, and ultimately phthisis bulbi, where the eye shrinks and loses all function PLOS.

Causes

  1. CAPN5 gene mutation
    A missense mutation in the CAPN5 gene is the fundamental cause of ADNIV, transmitted in an autosomal dominant pattern with complete penetrance PLOS.

  2. Exon 6 catalytic-domain alterations
    Mutations occur in exon 6 of CAPN5, affecting two adjacent amino acids critical for the enzyme’s catalytic activity PLOS.

  3. Mislocalization of calpain-5
    Disease-causing variants shift calpain-5 from its normal cell-membrane location to the cytosol, unsettling its regulation PLOS.

  4. Calcium-sensitive domain disruption
    The mutations lie within a calcium-binding domain, altering the enzyme’s activation threshold and response to calcium signals PLOS.

  5. Aberrant protease activity
    Structural changes near the enzyme’s active site result in unregulated proteolysis of intracellular proteins PLOS.

  6. Gain-of-function mechanism
    Unlike loss-of-function disorders, these mutations enhance calpain-5 activity, perpetuating tissue damage PLOS.

  7. Photoreceptor synapse dysfunction
    Calpain-5 normally modulates synaptic proteins; its mutated form disrupts photoreceptor-to-bipolar cell signaling, seen as ERG abnormalities PLOS.

  8. Intracellular signaling imbalance
    Excessive protease activity perturbs signaling networks that regulate cell survival, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation, and repair in the retina PLOS.

  9. Autoimmune activation
    Misprocessing of retinal proteins triggers autoimmune responses, leading to sterile infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation inside the eye PLOS.

  10. Immune cell infiltration
    Clusters of leukocytes invade the vitreous cavity, driving chronic uveitis and tissue injury PLOS.

  11. Blood–retinal barrier breakdown
    Inflammation compromises vessel integrity, allowing fluid to leak into the macula and cause edema PLOS.

  12. Pathologic neovascular growth
    Inflammatory signals promote abnormal new vessel formation on the retina and iris, which are fragile and prone to bleeding PLOS.

  13. Fibrotic membrane formation
    Persistent inflammation stimulates fibrous tissue deposition on retinal surfaces, leading to traction PLOS.

  14. Vitreous hemorrhage
    Fragile new vessels rupture easily, filling the vitreous cavity with blood and blocking vision PLOS.

  15. Neovascular glaucoma
    Aberrant vessels grow into the anterior chamber angle, impeding fluid outflow and raising intraocular pressure PLOS.

Symptoms

  1. Vision loss
    Gradual decrease in visual acuity occurs as photoreceptors degenerate and macular edema develops PLOS.

  2. Eye pain and redness
    Mild to moderate discomfort and redness accompany the intraocular inflammation of early stages PLOS.

  3. Photophobia
    Sensitivity to light arises from uveitis-related breakdown of the blood–aqueous barrier PLOS.

  4. Floaters
    Patients often note moving spots in their vision due to inflammatory cells or hemorrhages in the vitreous PLOS.

  5. Night blindness
    Early photoreceptor dysfunction leads to difficulty seeing in low-light conditions PLOS.

  6. Metamorphopsia
    Distorted or wavy central vision results from macular edema and epiretinal membrane formation PLOS.

  7. Cataract development
    Posterior subcapsular cataracts form prematurely, further reducing clarity of vision PLOS.

  8. Peripheral vision loss
    Retinal detachment and pigmentary degeneration shrink the visual field PLOS.

  9. Intraocular pressure spikes
    Neovascular and proliferative angle closure glaucoma cause episodic or sustained hypertension in the eye PLOS.

  10. End-stage phthisis bulbi
    In advanced disease, the eye becomes shrunken, disorganized, and non-functional PLOS.

Diagnostic Tests

Physical Examination

  1. Visual Acuity Test
    Measures the smallest letters a patient can read on a standardized chart, tracking progression of vision loss EyeWiki.

  2. Tonometry
    Gauges intraocular pressure to detect early neovascular glaucoma and steroid-induced spikes EyeWiki.

Manual Ophthalmic Examinations

  1. Slit-Lamp Examination
    Uses a biomicroscope to inspect the anterior segment for cells, flare, and cataracts EyeWiki.

  2. Gonioscopy
    Assesses the angle between the iris and cornea for neovascularization and angle-closure risk EyeWiki.

Laboratory and Pathological Tests

  1. Complete Blood Count (CBC)
    Screens for systemic inflammation and infection when uveitis is prominent EyeWiki.

  2. Erythrocyte Sedimentation Rate (ESR)
    Indicates nonspecific inflammatory activity that may accompany ocular inflammation EyeWiki.

  3. C-Reactive Protein (CRP)
    Another marker of systemic inflammation useful when ruling out infectious uveitis EyeWiki.

  4. Tuberculin Skin Test / IGRA
    Evaluates latent tuberculosis in patients with unexplained intraocular inflammation EyeWiki.

  5. RPR (Rapid Plasma Reagin)
    Screens for syphilis, a treatable cause of posterior uveitis EyeWiki.

  6. Genetic Testing for CAPN5
    Confirms the diagnosis by identifying pathogenic CAPN5 missense mutations PLOS.

Electrodiagnostic Tests

  1. Electroretinography (ERG)
    Detects early loss of the scotopic b-wave, indicating photoreceptor synapse dysfunction PLOS.

  2. Visual Evoked Potentials (VEP)
    Measures cortical responses to visual stimuli to assess optic nerve integrity EyeWiki.

  3. Electro-oculography (EOG)
    Assesses RPE function by measuring the standing potential between cornea and retina EyeWiki.

Imaging Tests

  1. Fundus Photography
    Documents the appearance of the retina, neovascular changes, and pigmentary degeneration EyeWiki.

  2. Fluorescein Angiography (FA)
    Visualizes blood-retinal barrier breakdown and areas of neovascular leakage PLOSEyeWiki.

  3. Optical Coherence Tomography (OCT)
    Provides cross-sectional images of the retina to detect macular edema and epiretinal membranes EyeWiki.

  4. B-Scan Ultrasonography
    Detects dense vitreous hemorrhage and tractional detachments when view is obscured EyeWiki.

  5. Indocyanine Green Angiography (ICGA)
    Highlights choroidal vasculature to evaluate deeper neovascularization EyeWiki.

  6. Fundus Autofluorescence
    Maps RPE integrity by detecting lipofuscin accumulation in degenerating photoreceptors EyeWiki.

  7. Widefield Retinal Imaging
    Captures peripheral retinal changes and vitreoretinal traction in advanced stages EyeWiki.

Non-Pharmacological Treatments

Below are twenty supportive and self-management strategies—categorized into exercise therapies, mind-body practices, and educational/self-management interventions—each explained in simple language with purpose and mechanism.

Exercise Therapies

  1. Brisk Walking
    Description: Gentle, sustained walking for 30 minutes most days.
    Purpose: Improves overall circulation and may reduce ocular inflammation.
    Mechanism: Regular aerobic exercise modulates immune cells and lowers pro-inflammatory cytokines that could exacerbate uveitis and neovascularization KargerPMC.

  2. Resistance Training
    Description: Light weights or resistance bands targeting major muscle groups, 2–3× weekly.
    Purpose: Builds strength, supports daily function, and may counter muscle loss from chronic inflammation.
    Mechanism: Increases anti-inflammatory myokines (e.g., IL-6) that help resolve systemic inflammation KargerPMC.

  3. Ocular Mobility Exercises
    Description: Slow, controlled eye movements (up, down, side-to-side) for 5–10 minutes daily.
    Purpose: Maintains flexibility of extraocular muscles and eases strain.
    Mechanism: Promotes micro-circulation in periocular tissues, which can aid fluid turnover in the vitreous cavity PatientUveitis.org | OIUF.

  4. Vision Rehabilitation Drills
    Description: Tracking moving targets on a screen or card, 15 minutes daily.
    Purpose: Slows progression of photoreceptor loss by stimulating surviving retinal cells.
    Mechanism: Neuroplasticity—repeated visual stimulation enhances synaptic strength in visual pathways PatientPMC.

  5. Balance and Coordination Tasks
    Description: Tai chi–style weight shifts or standing on a foam pad.
    Purpose: Improves proprioception to prevent falls and promote confidence in mobility.
    Mechanism: Engages vestibular and cerebellar circuits, indirectly supporting ocular motor control KargerPMC.

Mind-Body Practices

  1. Mindfulness Meditation
    Description: 10–20 minutes of guided breathing and present-moment focus.
    Purpose: Reduces stress that can trigger inflammatory flares.
    Mechanism: Lowers cortisol and sympathetic activation, dampening immune over-reactivity KargerAAO.

  2. Yoga
    Description: Gentle postures (asanas) with breath awareness, 2–3× weekly.
    Purpose: Enhances flexibility, reduces tension around head and neck, and calms the mind.
    Mechanism: Combines low-impact movement with parasympathetic activation to curb inflammation KargerAAO.

  3. Tai Chi
    Description: Flowing, low-impact martial art movements, 1-hour sessions.
    Purpose: Improves balance, reduces stress, and supports immune regulation.
    Mechanism: Synchronizes breath with motion, boosting vagal tone and lowering inflammatory markers KargerPMC.

  4. Guided Imagery
    Description: Visualization exercises imagining healing light in the eyes.
    Purpose: Eases anxiety and promotes a sense of control over illness.
    Mechanism: Influences limbic system to reduce stress hormone release KargerUveitis.org | OIUF.

  5. Deep-Breathing Techniques
    Description: 4-7-8 breathing (inhale 4s, hold 7s, exhale 8s) for 5 minutes.
    Purpose: Quickly calms the nervous system during acute discomfort or anxiety.
    Mechanism: Shifts autonomic balance toward parasympathetic dominance, which inhibits inflammatory cascades KargerAAO.

Educational & Self-Management Interventions

  1. Structured Patient Education Sessions
    Description: Regular classes or webinars about ADNIV and uveitis management.
    Purpose: Empowers patients with knowledge to adhere to treatments and recognize flares.
    Mechanism: Better understanding leads to earlier self-reporting of symptoms and timely intervention Uveitis.org | OIUFAAO.

  2. Support Group Participation
    Description: Monthly meetings (in-person or online) with fellow ADNIV patients.
    Purpose: Provides emotional support and practical tips from peers.
    Mechanism: Social connectedness reduces stress and encourages healthy coping strategies Uveitis.org | OIUFUveitis.org | OIUF.

  3. Symptom Self-Monitoring
    Description: Daily log of vision changes, pain, and floaters in a journal or app.
    Purpose: Helps detect subtle worsening before major complications arise.
    Mechanism: Early detection prompts faster clinical review and treatment adjustment Uveitis.org | OIUFPatient.

  4. Treatment Adherence Aids
    Description: Pillboxes, alarms, or medication-tracking apps.
    Purpose: Ensures consistent dosing of eye drops and systemic drugs.
    Mechanism: Reduces variability in drug levels, preventing flare-ups from missed doses PMCWebMD.

  5. Personalized Action Plans
    Description: Written plan outlining what to do at first sign of worsening.
    Purpose: Clears confusion during new symptoms, speeding self-care actions.
    Mechanism: Having predefined steps reduces decision fatigue and delays Uveitis.org | OIUFAAO.

  6. Telemedicine Check-Ins
    Description: Scheduled video visits with ocular immunologists.
    Purpose: Maintains close follow-up without travel barriers.
    Mechanism: Regular remote reviews catch flares early and adjust therapies promptly Uveitis.org | OIUFAAO.

  7. Online Educational Modules
    Description: Interactive e-learning about uveitis, genetics, and lifestyle.
    Purpose: Reinforces knowledge at one’s own pace and revisits complex topics.
    Mechanism: Multimedia content boosts retention and self-efficacy Uveitis.org | OIUFUveitis.org | OIUF.

  8. Peer Mentoring Programs
    Description: Pairing newly diagnosed patients with veteran ADNIV mentors.
    Purpose: Offers firsthand coping strategies and practical advice.
    Mechanism: Role modeling by experienced patients fosters constructive behaviors Uveitis.org | OIUFUveitis.org | OIUF.

  9. Stress Management Workshops
    Description: Group sessions teaching time management, relaxation, and resilience.
    Purpose: Equips patients to handle emotional ups and downs of chronic disease.
    Mechanism: Lowered stress correlates with fewer inflammatory flares KargerAAO.

  10. Caregiver Training
    Description: Instructional sessions for family on disease basics and assistance techniques.
    Purpose: Ensures supportive home environment and proper eye-drop administration.
    Mechanism: Educated caregivers help maintain adherence and spot early warning signs Uveitis.org | OIUFPatient.

Key Pharmacological Treatments

Below are ten cornerstone medications. For each, dosage, drug class, administration schedule, and common side effects are detailed.

  1. Prednisone (Oral Corticosteroid)

    • Dosage: Start at 1 mg/kg/day (max 60 mg) for acute flares, taper by 5 mg/week.

    • Class: Systemic corticosteroid.

    • Timing: Single morning dose to mimic circadian cortisol.

    • Side Effects: Weight gain, hypertension, hyperglycemia, osteoporosis, mood swings.

  2. Prednisolone Acetate 1% (Topical Steroid)

    • Dosage: One drop every 2 hours while awake for active inflammation, then taper over 6–8 weeks.

    • Class: Topical corticosteroid.

    • Timing: Throughout waking hours, spacing doses evenly.

    • Side Effects: Elevated intraocular pressure, cataract formation, delayed wound healing.

  3. Triamcinolone Acetonide (Periocular Injection)

    • Dosage: 20–40 mg sub-Tenon’s injection every 3–4 months as needed.

    • Class: Local corticosteroid injection.

    • Timing: Single injection per treatment cycle.

    • Side Effects: Localized ocular hypertension, orbital fat atrophy, ptosis.

  4. Fluocinolone Acetonide Intravitreal Implant (Iluvien)

    • Dosage: 0.18 mg implant placed via pars plana, lasting up to 36 months.

    • Class: Long-acting intravitreal corticosteroid.

    • Timing: Single implantation per eye.

    • Side Effects: High risk of steroid-response glaucoma, cataract progression EyeWiki.

  5. Bevacizumab (Avastin)

    • Dosage: 1.25 mg intravitreal injection every 4–6 weeks for neovascular suppression.

    • Class: Anti-VEGF monoclonal antibody.

    • Timing: Monthly injections initially, then PRN based on OCT.

    • Side Effects: Endophthalmitis risk, transient intraocular inflammation.

  6. Ranibizumab (Lucentis)

    • Dosage: 0.5 mg intravitreal injection monthly for 3 months, then PRN.

    • Class: Anti-VEGF Fab fragment.

    • Timing: Monthly loading doses, then as needed.

    • Side Effects: Rare systemic thromboembolic events, eye pain.

  7. Aflibercept (Eylea)

    • Dosage: 2 mg intravitreal injection every 8 weeks after 3 initial monthly doses.

    • Class: VEGF-trap fusion protein.

    • Timing: 3 monthly loading, then bi-monthly maintenance.

    • Side Effects: Elevated intraocular pressure, conjunctival hemorrhage.

  8. Methotrexate (Systemic Immunosuppressant)

    • Dosage: 15–25 mg subcutaneous weekly, with folinic acid rescue.

    • Class: Antimetabolite immunosuppressant.

    • Timing: Once weekly.

    • Side Effects: Hepatotoxicity, bone marrow suppression, mucositis.

  9. Azathioprine

    • Dosage: 1–2 mg/kg/day orally.

    • Class: Purine analog immunosuppressant.

    • Timing: Daily.

    • Side Effects: Leukopenia, hepatotoxicity, increased infection risk.

  10. Infliximab (Remicade)

  • Dosage: 5 mg/kg intravenous infusion at weeks 0, 2, 6, then every 8 weeks.

  • Class: Anti-TNF-α monoclonal antibody.

  • Timing: Loading then maintenance infusions.

  • Side Effects: Infusion reactions, latent tuberculosis reactivation.

Dietary Molecular Supplements

These supplements may support retinal health by reducing oxidative stress and modulating inflammation.

  1. Vitamin A (Retinol)

    • Dosage: 3,000 IU/day.

    • Function: Essential for photoreceptor function.

    • Mechanism: Maintains rod and cone pigment regeneration.

  2. Vitamin C (Ascorbic Acid)

    • Dosage: 500 mg twice daily.

    • Function: Water-soluble antioxidant.

    • Mechanism: Scavenges free radicals in ocular tissues.

  3. Vitamin E (α-Tocopherol)

    • Dosage: 400 IU/day.

    • Function: Lipid-soluble antioxidant.

    • Mechanism: Protects photoreceptor membranes from peroxidation.

  4. Zinc

    • Dosage: 40 mg elemental zinc/day.

    • Function: Cofactor for antioxidant enzymes.

    • Mechanism: Stabilizes cell membranes and supports superoxide dismutase.

  5. Omega-3 Fatty Acids (DHA/EPA)

    • Dosage: 1,000 mg DHA + 500 mg EPA daily.

    • Function: Anti-inflammatory lipid mediators.

    • Mechanism: Reduces cytokine production and vascular permeability.

  6. Lutein

    • Dosage: 10 mg/day.

    • Function: Macular pigment enhancement.

    • Mechanism: Filters blue light and neutralizes reactive oxygen species.

  7. Zeaxanthin

    • Dosage: 2 mg/day.

    • Function: Supports central retinal health.

    • Mechanism: Synergizes with lutein for macular protection.

  8. Curcumin

    • Dosage: 500 mg twice daily.

    • Function: Natural anti-inflammatory.

    • Mechanism: Inhibits NF-κB and downregulates TNF-α production.

  9. Resveratrol

    • Dosage: 150 mg/day.

    • Function: Polyphenolic antioxidant.

    • Mechanism: Activates SIRT1, promoting cell survival pathways.

  10. Quercetin

  • Dosage: 500 mg twice daily.

  • Function: Bioflavonoid with anti-angiogenic effects.

  • Mechanism: Inhibits VEGF signaling and vascular permeability.

Emerging Pharmacological Approaches

These therapies are investigational or off-label, focusing on novel mechanisms.

  1. Alendronate (Bisphosphonate)

    • Dosage: 70 mg orally weekly.

    • Function: Anti-angiogenic potential.

    • Mechanism: Inhibits farnesyl pyrophosphate synthase, reducing endothelial proliferation.

  2. Risedronate (Bisphosphonate)

    • Dosage: 35 mg orally weekly.

    • Function: Modulates inflammatory cell activity.

    • Mechanism: Reduces macrophage-mediated cytokine release.

  3. Recombinant Human FGF2 (Regenerative)

    • Dosage: Intravitreal 50 µg monthly (investigational).

    • Function: Stimulates neuronal and vascular repair.

    • Mechanism: Binds FGFR, promoting Müller cell survival and angiostatic balance.

  4. PEDF-Derived Peptides (Regenerative)

    • Dosage: Intravitreal injections every 8 weeks (trial doses).

    • Function: Neuroprotective and anti-angiogenic.

    • Mechanism: Inhibits VEGF and supports photoreceptor integrity.

  5. Hyaluronic Acid Vitreous Substitute (Viscosupplementation)

    • Dosage: Single pars plana injection at vitrectomy (exact dose varies).

    • Function: Restores vitreous volume and damping.

    • Mechanism: Provides scaffold for controlled drug release and mechanical support.

  6. Mesenchymal Stem Cell Injection (Stem Cell Therapy)

    • Dosage: Sub-Tenon’s or intravitreal 1×10⁶ cells (ongoing trials).

    • Function: Anti-inflammatory and regenerative.

    • Mechanism: Secretes trophic factors (e.g., HGF, TSG-6) that modulate immune response and promote retinal repair.

Surgical Interventions

When medical therapy is insufficient, surgical procedures can restore anatomy and control complications.

  1. Pars Plana Vitrectomy (PPV)

    • Procedure: Removal of vitreous gel via three-port entry, clearing inflammatory debris and membranes.

    • Benefits: Reduces cytokine load, allows direct membrane peeling, and facilitates drug delivery EyeWiki.

  2. Epiretinal Membrane Peeling

    • Procedure: Carefully lifting fibrocellular membranes from the retinal surface under visualization.

    • Benefits: Relieves retinal traction, improves macular contour, and may enhance visual acuity.

  3. Panretinal Photocoagulation (PRP)

    • Procedure: Laser burns applied across peripheral retina to regress neovascularization.

    • Benefits: Reduces VEGF drive, prevents vitreous hemorrhage, and lowers risk of neovascular glaucoma.

  4. Cataract Extraction with Intraocular Lens Implantation

    • Procedure: Phacoemulsification of the crystalline lens and placement of a foldable intraocular lens.

    • Benefits: Addresses steroid-induced or disease-related cataracts, improving rehabilitation of vision.

  5. Glaucoma Drainage Device Placement

    • Procedure: Implantation of Ahmed or Baerveldt valve to shunt aqueous humor.

    • Benefits: Controls steroid-response or neovascular glaucoma pressure spikes that are refractory to medications.

Preventive Measures

Preventing exacerbations and preserving remaining vision involves lifestyle and environmental modifications:

  1. Genetic counseling for at-risk family members

  2. Avoiding tobacco smoke and second-hand exposure

  3. Wearing UV-blocking sunglasses outdoors

  4. Maintaining tight control of systemic comorbidities (e.g., diabetes, hypertension)

  5. Adhering to a Mediterranean-style, antioxidant-rich diet

  6. Regular moderate exercise (≥150 minutes/week)

  7. Moderating alcohol intake (<1 drink/day for women, <2 for men)

  8. Ensuring adequate sleep hygiene (7–8 hours/night)

  9. Keeping indoor air quality high (humidifiers/HEPA filters to reduce irritants)

  10. Scheduling routine comprehensive eye exams at least twice yearly

When to See Your Doctor

Seek prompt medical attention if you experience:

  • Sudden decrease in vision or new blind spots

  • Intense eye pain or headache with redness

  • New floaters, flashes of light, or curtain-like vision loss

  • Severe sensitivity to light (photophobia)

  • Uncontrolled eye pressure symptoms (halos around lights)

“Do’s” and “Don’ts”

Do:

  1. Follow your medication schedule exactly as prescribed

  2. Use prescribed eye drops at recommended intervals

  3. Keep a symptom diary and share it at visits

  4. Apply cold compresses for mild eye discomfort

  5. Wear protective eyewear during sports or chores

Avoid:
6. Rubbing or pressing on inflamed eyes
7. Missing outpatient follow-up or lab testing appointments
8. Self-medicating with over-the-counter NSAID drops without approval
9. Exposure to smoky or dusty environments
10. Skipping vaccinations (e.g., influenza) that can trigger systemic inflammation

Frequently Asked Questions (FAQs)

  1. What is the cause of ADNIV?
    ADNIV is caused by dominant missense mutations in the CAPN5 gene, leading to toxic hyperactivity of the calpain-5 enzyme in retinal cells Via Medica Journals.

  2. How is ADNIV inherited?
    It follows an autosomal dominant pattern: each child of an affected parent has a 50% chance of inheriting the mutation.

  3. At what age do symptoms begin?
    Onset typically occurs between the second and fourth decades of life, but initial signs may be subtle and underdiagnosed.

  4. Can ADNIV be cured?
    There is currently no cure. Management focuses on controlling inflammation, preventing complications, and preserving vision.

  5. Is genetic testing available?
    Yes. Clinical genetic laboratories offer CAPN5 mutation analysis for definitive diagnosis and family counseling.

  6. What are the main treatments?
    Long-term corticosteroids (topical, systemic, or implant), anti-VEGF agents, immunosuppressants, and timely vitrectomy or laser procedures form the treatment backbone EyeWiki.

  7. How often should I have follow-up exams?
    Typically every 1–3 months or more frequently during active inflammation or after surgical interventions.

  8. Can lifestyle changes slow disease progression?
    Yes. Regular exercise, healthy diet, UV protection, and stress management can help modulate systemic inflammation.

  9. Are there risks with long-term steroid use?
    Chronic steroids can cause cataracts, glaucoma, hypertension, and osteoporosis; careful monitoring is essential.

  10. What surgical risks exist?
    Vitrectomy and implants carry risks of infection, bleeding, and increased intraocular pressure but can be vision-saving.

  11. Is low-vision rehabilitation helpful?
    Absolutely. Occupational therapy, Magnifier use, and adaptive technologies enhance daily function as vision declines.

  12. Do children require different management?
    Pediatric cases often present later symptomatically; genetic confirmation is vital, and dosing adjustments are needed for weight and growth.

  13. Are clinical trials available?
    Emerging RNA-interference therapies and novel anti-calpain agents are under investigation; referral to specialized centers is recommended.

  14. Can pregnancy affect ADNIV?
    Hormonal changes may modulate immune activity; close obstetric-ophthalmic collaboration is advised.

  15. What is the long-term outlook?
    Without aggressive, sustained therapy, most patients progress to severe vision loss by their sixth decade; proactive management can delay this trajectory.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 14, 2025.

 

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Doctor / qualified healthcare provider
Tests to discuss with doctor
  • Basic vital signs: temperature, pulse, blood pressure, oxygen level if needed
  • Relevant blood, urine, imaging, or specialist tests only after clinical assessment
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Is this article a replacement for a doctor?

No. It is educational content only. Patients should consult a qualified clinician for diagnosis and treatment.

When should I seek urgent care?

Seek urgent care for severe symptoms, rapidly worsening condition, breathing difficulty, severe pain, neurological changes, or any emergency warning sign.

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Congenital Iris Ectropion

    Congenital? iris ectropion is more commonly called congenital? ectropion uveae. It is a rare developmental eye condition present from birth in which the dark pigment layer...

    April 2, 2026 • Rx Eye & Vision Care (A - Z)
  2. Congenital Cystic Eyeball

    Congenital? cystic eyeball, also called congenital? cystic eye, is a very rare birth defect in which a cyst forms in the eye socket and the normal...

    March 31, 2026 • Rx Eye & Vision Care (A - Z)
  3. Congenital Anophthalmos with Cyst

    Congenital? anophthalmos with cyst is a very rare birth defect of eye development. In this condition, a child is born without a normally formed eye in...

    March 31, 2026 • Rx Eye & Vision Care (A - Z)
  4. Congenital Cystic Eye

    Congenital? cystic eye is a very rare birth condition. In this condition, a cyst-like sac grows in the eye socket where the eye should normally form....

    March 31, 2026 • Rx Eye & Vision Care (A - Z)
  5. Cerulean Cataract

    Cerulean cataract is a rare kind of childhood or developmental cataract. A cataract means the natural lens of the eye becomes cloudy instead of staying clear....

    March 12, 2026 • Rx Eye & Vision Care (A - Z)
  6. Congenital Blue Dot Cataract

    Congenital? blue dot cataract, also called cerulean cataract, is a type of childhood lens opacity in which many tiny bluish or whitish dots appear in the...

    March 12, 2026 • Rx Eye & Vision Care (A - Z)
  7. Congenital Achiasma

    Congenital? achiasma is a very rare eye and brain problem that is present from birth. It happens when the optic chiasm, the “cross-road” where nerve fibers...

    March 5, 2026 • Rx Eye & Vision Care (A - Z)
  8. Congenital Absence of Lacrimal Puncta and Salivary Glands

    Congenital? absence of lacrimal puncta and salivary glands means that a baby is born without the tiny tear drainage openings on the eyelids (lacrimal puncta) and...

    March 5, 2026 • Rx Eye & Vision Care (A - Z)
  9. Aplasia of the Lacrimal and Salivary Glands

    Aplasia of the lacrimal and salivary glands means that the tear glands and saliva glands did not grow properly before birth. They are partly formed, very...

    March 5, 2026 • Rx Eye & Vision Care (A - Z)
  10. Cone-Rod Dystrophy Type 6

    Cone-rod dystrophy type 6 (often written as CORD6) is a rare eye disease that slowly damages the light-sensing cells (cones and rods) in the retina, the...

    March 4, 2026 • Rx Eye & Vision Care (A - Z)